Clinical trials: Interstitial Lung Fibrosis
Pulmonary Fibrosis, Sarcoidosis
Fibrosing ILD Biomarkers That Rule Acceleration
FIBRALUNG is a prospective cohort study with biobank of samples from patients with pulmonary fibrosis, aiming to explore the molecular determinants of different clinical outcomes, acute exacerbations and mortality.
- Trial name
- FIBRALUNG (NCT05635032)
- Testing
- Comprehensive clinical assessment and biological samples collection
- Where
- Portugal
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Universidade do Porto
Idiopathic Pulmonary Fibrosis (IPF)
A Phase I Study of HW241045 in Healthy Subjects
This is a Phase I, randomized, double-blind, placebo-controlled study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and food effect (FE) of HW241045 in healthy participants.
- Trial name
- NCT07593690
- Testing
- HW241045 Formulation A, HW241045 Formulation B
- Where
- China
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.
Idiopathic Pulmonary Fibrosis (IPF)
Biomarker Discovery for Novel Drug Development in Idiopathic Pulmonary Fibrosis
Drug discovery can take many years especially since most studies to measure effectiveness depend on clinical outcomes like pulmonary function tests and hospitalizations.
- Trial name
- NCT01718990
- Where
- United States
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Idiopathic Pulmonary Fibrosis(IPF), Solid Tumor
Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Ascending Dose of ZSP1603 in Healthy Adults
The Primary objectives of this study are to evaluate the safety and tolerability of ZSP1603 and the Secondary objective is to estimate the pharmacokinetic (PK) parameters after orally administered once daily of ZSP1603.
- Trial name
- NCT03619616
- Testing
- ZSP1603 7.5 mg, ZSP1603 12.5 mg, ZSP1603 25 mg
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Guangdong Zhongsheng Pharmaceutical Co., Ltd.
Idiopathic Pulmonary Fibrosis (IPF)
A Study of the Pharmacokinetic Interaction Between Pirfenidone and BMS-986278 in Healthy Participants
The main objectives of this study are to characterize the PK of BMS-986278 after administration of a single dose of BMS-986278 alone or in combination with pirfenidone, as well as to characterize the PK of pirfenidone after…
- Trial name
- NCT03981094
- Testing
- BMS-986278, Pirfenidone
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Idiopathic Pulmonary Fibrosis
Using MRI to Visualize Regional Therapy Response in Idiopathic Pulmonary Fibrosis
The purpose of this study is to determine whether magnetic resonance imaging (MRI) using inhaled hyperpolarized 129Xe gas, and conventional contrast can help visualize impaired lung function and detect changes over time in…
- Trial name
- NCT02478268
- Testing
- Hyperpolarized 129-Xenon gas, MRI
- Where
- 2 sites in United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Bastiaan Driehuys
Pulmonary Fibrosis
Telomeres Length in Israeli Fibrotic ILD Patients
Individuals with fibrotic interstitial lung diseases (FILD) will be recruited after providing informed consent. in addition to routine data as usually collected in the clinic, blood samples will be taken for measurement of…
- Trial name
- NCT06885515
- Testing
- leukocyte telomere length (LTL) will be measured using the Telomere Restriction Fragment (TRF) Analysis method
- Where
- 2 sites in Israel
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Barzilai Medical Center
Idiopathic Pulmonary Fibrosis
Study To Investigate The Potential DDI Between HEC585 And Pirfenidone/Nintedanib In Healthy Subjects
A single-center, open-label study designed to assess the drug-drug interaction of HEC585 and pirfenidone in healthy male and female subjects.
- Trial name
- NCT07588646
- Testing
- HEC585, Nintedanib, Pirfenidone
- Where
- China
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis
Toward Self-management in ILD
Treating and caring for people with long term conditions accounts for a substantial proportion of health care resources. Self-management is advocated as a mechanism that can empower service users with long term conditions to…
- Conditions
- Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis, Connective Tissue Related ILD, Chronic Hypersensitivity Pneumonitis
- Trial name
- NCT03300583
- Testing
- Focus groups, Semi-structured interviews
- Where
- 2 sites in United Kingdom
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Kingston University
Idiopathic Pulmonary Fibrosis, Primary Sclerosing Cholangitis
Detection of Integrin avb6 in IPF, PSC, and COVID19 Using PET/CT
Detection of Integrin avb6 in Idiopathic Pulmonary Fibrosis, Primary Sclerosing Cholangitis, and Coronavirus Disease 2019 with [18F]FP-R01-MG-F2 with PET/CT
- Conditions
- Idiopathic Pulmonary Fibrosis, Primary Sclerosing Cholangitis, Covid19 Pneumonia
- Trial name
- NCT03183570
- Testing
- [18F]FP-R01-MG-F2
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Stanford University
Idiopathic Pulmonary Fibrosis (IPF)
TD-1058 First-In-Human Study in Healthy Subjects and Subjects With Idiopathic Pulmonary Fibrosis
This is a Phase 1, 4-part, randomized, double-blinded, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of TD-1058 inhaled solution.
- Trial name
- NCT04589260
- Testing
- TD-1058
- Where
- United Kingdom
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Theravance Biopharma
Pulmonary Fibrosis
Supplemental Oxygen in Pulmonary Fibrosis
To enhance understanding of supplemental oxygen-its utility in and adoption by patients with pulmonary fibrosis-by examining how patients perceive it and by determining how perceptions and patient-centered outcome measures change…
- Trial name
- NCT01961362
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- National Jewish Health
Idiopathic Pulmonary Fibrosis
Assess the Safety, Tolerability and Pharmacokinetics of AZD5055 Following Single and Multiple Ascending Doses in Healthy Participants
This is a phase I, First-in-Human study in healthy participants, performed at a single study center, consisting of 2 parts: Part 1 is a single ascending dose (SAD) study and Part 2 is a multiple ascending dose (MAD) study.
- Trial name
- NCT05134727
- Testing
- AZD5055
- Where
- United States
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Idiopathic Pulmonary Fibrosis, Hypersensitivity Pneumonitis
129Xe Gas Exchange Imaging in IPF and cHP: A Reliability Study
This research is a study to test the reliability of Hyperpolarized Xenon MRI (HXe MRI) as a biomarker in interstitial lung disease.
- Trial name
- NCT04677426
- Testing
- Hyperpolarized Xe129
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Kansas Medical Center
Idiopathic Pulmonary Fibrosis
To Evaluate Food Effect on the PK and Safety After Oral DWN12088 Administration in Healthy Adult Volunteers
The pharmacokinetics (PK) and safety of single oral dose of DWN12088 in healthy adults will be compared and assessed on an empty stomach, after high-fat meal, or 2 hours after high-fat meal.
- Trial name
- NCT04767815
- Testing
- Diet A group, Diet B group, Diet C group
- Where
- South Korea
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Healthy Participants
A Study Investigating the Safety, Tolerability, Drug Levels and Drug Effect of BMS-986278 in Healthy Adult Participants (Part 1) and Japanese Participants (Part 2)
The purpose of this study is to evaluate the safety, tolerability, drug levels and drug effect of BMS-986278 in healthy adult participants and Japanese participants.
- Trial name
- NCT05684289
- Testing
- BMS-986278, Sildenafil
- Where
- 2 sites in United States
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Pulmonary Fibroses, Idiopathic
Study to Assess CMR316 in Healthy Volunteers and Patients With Idiopathic Pulmonary Fibrosis
The purpose of this study is to assess the safety, tolerability and pharmacokinetics single and multiple inhaled doses of CMR316 in healthy volunteers and patients with Idiopathic Pulmonary Fibrosis (IPF).
- Trial name
- NCT06589219
- Testing
- CMR316
- Where
- Germany
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- Calibr, a division of Scripps Research
Pulmonary Fibrosis, Lung Cancer
Preliminary Evaluation of [68Ga]CBP8 in Healthy Individuals, Lung Cancer, and Idiopathic Pulmonary Fibrosis Patients
The goal of this study is to investigate the safety of [68Ga]CBP8 and its efficacy to detect collagen deposition in pulmonary fibrosis.
- Trial name
- NCT03535545
- Testing
- [68Ga]CBP8, PET Imaging
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Idiopathic Pulmonary Fibrosis, Lung; Disease, Interstitial, With Fibrosis
A Study to Evaluate Safety, Tolerability and Pharmacokinetics of RSN0402 in Healthy Volunteers
This is a phase 1, randomized, First in Human (FIH), double-blinded, placebo-controlled study to assess the safety, tolerability, and PK of RSN0402 in healthy volunteers.
- Trial name
- NCT06482190
- Testing
- RSN0402 Part 1, RSN0402 Part 2
- Where
- 3 sites in Australia
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Shenzhen Resproly Biopharmaceutical Co., Ltd
Idiopathic Pulmonary Fibrosis
A Validation and Dosimetry Study of GSK2634673F PET Ligand
This is a methodology study to examine the quantification of GSK2634673F binding in humans, with the aim of characterising a robust, non-invasive method to quantify the specific binding signal for the alpha(V)beta6 protein in…
- Trial name
- NCT02052297
- Testing
- GSK2634673F
- Where
- 2 sites in United Kingdom
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline